A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A children's oncology group study

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1516-1522

  Horton, Terzah M ^a   Pati, Debananda ^a   Plon, Sharon E ^a   Thompson, Patrick A ^a   Bomgaars, Lisa R ^a   Adamson, Peter C ^b   Ingle, Ashish M ^c   Wright, John ^d   Brockman, Adam H ^f   Paton, Martin ^e   Blaney, Susan M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

^f Merck Research Laboratories Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BONE MARROW APLASIA; BONE MARROW TRANSPLANTATION; BONE PAIN; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; LEUKEMIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NERVE PARALYSIS; ONCOLOGY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; I-KAPPA B KINASE; IMMUNOBLOTTING; INFANT; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 33947362982     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2173     Document Type: Article

References (19)

1. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
2. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
3. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21.
4. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
5. Masdehors P, Merle-Beral H, Magdelenat H, Delic J. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma 2000;38:499-504.
6. Soligo D, Servida F, Delia D, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001;113:126-35.
7. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75.
8. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
9. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004;22:4752-7.
10. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004;10:3371-6.
11. DiArgenio DZ, Schumitsky A. ADAPT II Users Guide: pharmacokinetic/ pharmacodynamic systems analysis software. (4). 1997. Los Angeles, CA, Biomedical Systems Resource.
12. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
13. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21.
14. Aghajanian C, Soignet SL, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
15. Millennium Pharmaceuticals, Inc., PS-341 investigator brochure 2004. p. 66.
16. Brown RE, Bostrom B, Zhang PL. Morphoproteomics and bortezomib/ dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci 2004;34:203-5.
17. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2005;58:13-23.
18. Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000;96:269-74.
19. Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006;5:745-8.